1. Subcutaneous immunoglobulin (SCIG) for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), a multicenter randomized double-blind placebo-controlled trial: The PATH Study. Issue 1 (January 2019) Authors: Cocito, D.; Peci, E.; Lauria Pinter, G.; Dacci, P.; Di Muzio, A.; Telese, R.; Schenone, A.; Benedetti, L.; Antonini, G.; Morino, S.; Sorbi, S.; Matà, S.; Bril, V.; van Geloven, N.; Hartung, H.-P.; Lewis, R.A.; Sobue, G.; Lawo, J.-P.; Mielke, O.; Durn, B.L. Journal: Clinical neurophysiology Issue: Volume 130:Issue 1(2019:Jan.) Page Start: e10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Feasibility of switching from intravenous to subcutaneous immunoglobulin in CIDP: PATH trial and clinical experience. Issue 1 (January 2019) Authors: Cocito, D.; Peci, E.; Lauria Pinter, G.; Dacci, P.; Di Muzio, A.; Telese, R.; Schenone, A.; Benedetti, L.; Antonini, G.; Morino, S.; Sorbi, S.; Matà, S.; Bril, V.; van Geloven, N.; Hartung, H-P.; Lewis, R.A.; Sobue, G.; Lawo, J.-P.; Mielke, O.; Durn, B.L. Journal: Clinical neurophysiology Issue: Volume 130:Issue 1(2019:Jan.) Page Start: e12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗